IDH1 and central nervous system cancer: The most recent cIMPACT update on IDH-WT infiltrating gliomas recommends upgrading of infiltrating gliomas bearing EGFR amplification and/or 7 gain/10 loss and/or TERT mutation as glioblastoma equivalents.